Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pembrolizumab Q6W in Relapsed or Refractory cHL or PMBCL
NCT04875195Phase 2Completed
- Sponsor
- Merck & Co.
- Start
- Jun 2021
- Primary completion
- Dec 2023
- Modality
- Immune Checkpoint Inhibitors, Recombinant Proteins and Enzymes
- Countries
- 11
01
Overview
A Phase 2 trial of pembrolizumab in Hodgkin lymphoma (HL), primary mediastinal large B-cell lymphoma (PMBCL), sponsored by Merck & Co.. Started Jun 2021; status: completed.
02
Drugs
03
Conditions
Hodgkin lymphoma (HL)primary mediastinal large B-cell lymphoma (PMBCL)
Beyond the preview
Go deeper on NCT04875195.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04875195.